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COURAGE Under Fire
On the Management of Stable Coronary Disease
George A. Diamond, MD, FACC, Sanjay Kaul, MD, FACC
Los Angeles, California
The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial showed that
coronary interventional procedures added little to optimal medical therapy with respect to the long-term out-
come of patients with stable coronary disease when used as initial therapy. Detractors opine that: 1) the trial
was unrealistic in design and the findings were not unexpected; 2) the use of coronary interventional procedures
was suboptimal; and 3) the results of COURAGE are not applicable to current clinical practice. We herein reeval-
uate the evidence with regard to each of these points, and conclude that COURAGE indeed provides relevant
new information to assist the practitioner in the appropriate management of patients with stable coronary
disease (J Am Coll Cardiol 2007;50:1604–9) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.010t
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tccording to Schopenhauer (1), truth passes through 3
tages: “First, it is ridiculed. Second, it is violently opposed.
hird, it is accepted as being self-evident.” Kereiakes et al.
2) reverse this journey in their review of the COURAGE
Clinical Outcomes Utilizing Revascularization and Ag-
ressive Drug Evaluation) trial and its conclusion that
ercutaneous coronary intervention (PCI) adds little to
ptimal medical therapy (OMT) in the management of
table coronary disease (3). In the present counterpoint, we
evisit each signpost and proffer a more optimistic view of
he landscape.
tage 3: “it is. . .self-evident”
oint. Kereiakes et al. (2) claim that the COURAGE trial
as “neither surprising nor new” compared with previous
tudies (4). Given what was already known, “COURAGE
et an unrealistic goal” by enrolling a small select group of
elatively low-risk patients and seeking to detect a large
eduction in death or myocardial infarction (MI). In-
tead, “a noninferiority trial design may have been more
ppropriate” (2).
ounterpoint. In fact, enrollment criteria in the COUR-
GE trial were entirely conventional. Clinical equipoise
nd the usual desiderata of trial design necessitated exclu-
ions at both extremes of risk (serious comorbidity and New
ork Heart Association (NYHA) functional class IV angina
t the high end versus undocumented ischemia and 70%
tenosis at the low end), thereby assuring a homogeneous,
lbeit small, study population (6.4% of 35,539 candidates in
rom the Division of Cardiology, Cedars-Sinai Medical Center, and the David
effen School of Medicine, University of California, Los Angeles, California.t
Manuscript received August 9, 2007; revised manuscript received August 17, 2007,
ccepted August 27, 2007.he COURAGE trial versus 2.9% of 20,769 candidates in
he MASS [Medicine, Angioplasty, or Surgery Study]-II
rial [5]).
The COURAGE trial was conceived in 1996, and at the
ime of its design in 1999, 6 trials comprising 1,872 patients
ith stable coronary disease had already been published (4).
he rate of death or MI was 7.2% for medical therapy versus
.6% for PCI (20% more) over 6 to 57 months. The
OURAGE trial relied instead on a consensus that PCI
ould perform as well in stable coronary disease as it was
hought to do in acute coronary syndromes (W.S. Wein-
raub, personal communication, June 29, 2007), and its
onsequent expectation of a 22% risk reduction over 3 years
6) was indeed “unrealistic” (2). Two contemporary
eta-analyses (7,8) confirm the benefit of PCI in acute
oronary syndromes (Table 1), although a similar meta-
nalysis (exclusive of the COURAGE trial) shows no
omparable benefit in stable coronary disease (Table 2). In
his context, the findings in the COURAGE trial are
ndeed not “new” (2).
But there is more to the story. Table 3 updates Table 2
ith the data from the COURAGE trial relative to the
ypothesis that PCIOMT improves death or MI better
han OMT in stable coronary disease, thereby circumvent-
ng any post hoc considerations of statistical power and
ssessing the actual observations without regard for what
ight have been observed (9). Independent of any “unreal-
stic” expectations, OMT is favored by a ratio of nearly 7:1.
Nevertheless, because the lay public is unlikely to distin-
uish between unstable and stable disease, most patients
ndergoing elective PCI often do so under the belief that it
ndeed prolongs their life or prevents a heart attack. The fact
hat most (10,11) of these procedures are performed elec-
ively—often in stable patients immediately following ad
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October 16, 2007:1604–9 On the Management of Stable Coronary Diseaseoc diagnostic angiography (12)—only serves to reinforce
his belief. At the very least, then, physicians and patients
learly act as if they believe PCI prevents death and MI in
table coronary disease.
If, as Kereiakes et al. (2) claim, the principal benefit of
CI in stable disease lies in “the relief of symptoms and
mprovement in quality of life,” why then are these proce-
ures being performed in asymptomatic patients (13)? And
hy are some of us so enthusiastically recommending
creening tests to identify asymptomatic patients for coro-
ary revascularization (14–16)?
Current guidelines actually encourage such practice by
ndorsing PCI as “reasonable” (Class IIa) in asymptomatic
atients with suitable anatomy, viable myocardium, and
emonstrable ischemia on noninvasive testing (17) on the
pecious assumption that silent ischemia is a surrogate for
ngina. In symptomatic patients, the guidelines properly
estrict PCI to those “who have not been successfully treated
y medical therapy,” saying that “the goal of treatment
hould be complete, or nearly complete, elimination of
nginal chest pain” (18).
If so, PCI comes up short. Only 66% of PCI patients in
he COURAGE trial were angina free at 1 year versus 58%
or OMT (12% started out that way), and its statistical
uperiority lasted for only 3 years (3), after which restenosis
r atherosclerotic progression very likely intervened. The
robability that PCIOMT improves angina-free status
etter than OMT by more than 10% is only 58% at 1 year,
5% at 3 years, and 4% at 5 years (Table 4). This less than
tellar performance is arguably the most “novel” contribu-
ion of the COURAGE trial. Percutaneous coronary inter-
ention performed somewhat better in the smaller
ASS-II trial (5,19), largely because medical therapy was
ot as aggressive as in the COURAGE trial (angina-free
tatus for PCI vs. medical therapy was 52% vs. 36% at 1 year
nd 77% vs. 55% at 5 years). If these findings were to cause
s to rethink our expectations of antianginal therapy, that
lone would be “surprising [and] new” (2).
Should the COURAGE trial have been a noninferiority
rial (2)? Using our 7.2% event rate (4) for the active control
aseline and a noninferiority margin of 1.4% (a 20%
ifference), such a trial (20) requires 12,242 patients—5
imes that in the COURAGE trial (6). But suppose there
ere sufficient resources and resolve to perform this daunt-
ng trial. There are 2 possible outcomes: either PCIOMT
eets criteria for noninferiority or it does not. If not, it must
e slightly inferior (having a hazard ratio of 1.05 accord-
eta-Analyses of PCI in Acute Coronary Syndromes
Table 1 Meta-Analyses of PCI in Acute Coronary Syndromes
End Point
Bavry et al. (7)
OR (95% CI)
Death 0.75 (0.63–0.90)
Nonfatal MI 0.83 (0.72–0.96)
Rehospitalization 0.69 (0.65–0.74)I  confidence interval; MI  myocardial infarction; OR  odds ratio; PCI  percutaneous coronary inteng to the COURAGE trial),
hereby making OMT the pre-
erred option. But if PCIOMT
ere adjudged noninferior to
MT, on what basis could one
hen say it should be preferred?
oes PCI make OMT safer?
ess costly? More convenient?
ore practical? More accessible?
tage 2: “it is violently
pposed”
oint. Kereiakes et al. (2) contend that PCI was not
ptimally performed in the COURAGE trial. They argue
hat if: 1) a core laboratory had assessed the angiographic
ndings; 2) more patients had been treated in non-Veterans
ffairs (VA) hospitals; 3) crossovers had been less; 4) the
tudy had been limited to high-risk patients; 5) the defini-
ion of periprocedural MI had been more forgiving; and 6)
rug-eluting stents (DES) had been used more freely—then
he outcomes and conclusions would have been different.
et us take up each of these points in turn.
ounterpoint. By all accounts, the standard of perfor-
ance in COURAGE was high. The 21% rate of “addi-
ional revascularization” (3) is actually less than in ARTS
Arterial Revascularization Therapies Study; 23%) and the
ASS-II trial (32%) over comparable follow-up (5,21), and
ts median of 10 months indicates that about one-half these
vents occurred in the first year. If, as is likely, this is a
onsequence of restenosis, it is less than that of bare-metal
tenting (22). Moreover, although only one-half of the
atients with multivessel disease received multiple stents,
his too is comparable to the MASS-II trial (5) and higher
han in the New York State Angioplasty Registry (23).
inally, although bypass surgery clearly provides more
omplete revascularization than PCI, it does not prevent
ore death or MI (5,21,24).
The design of the COURAGE trial specifically calls for
ll angiograms being “read centrally by a core angiographic
aboratory” (6). Even if it had not, it is hard to imagine how
his would impact angiographic or clinical outcomes as
mplied (2). For obvious reasons, physicians responsible for
ay-to-day care cannot wait for post hoc readings. But if
his were necessary to the effectiveness of PCI, what would
e the implications for the typical hospital performing these
rocedures on an ad hoc basis (12)?
Mehta et al. (8)
alue OR (95% CI) p Value
01 0.92 (0.77–1.09) 0.33
12 0.75 (0.65–0.88) 0.001
001 0.66 (0.60–0.72) 0.001
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
MI  myocardial infarction
NYHA  New York Heart
Association
OMT  optimal medical
therapy
PCI  percutaneous
coronary interventionp V
0.0
0.0
0.0rvention.
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On the Management of Stable Coronary Disease October 16, 2007:1604–9Although sample size restrictions limit the reliability of
ubgroup analyses, there are no significant differences in
utcome between VA and non-VA systems (p 0.19). There
s therefore no reason to believe that the observed site-to-site
ariability differs from that in actual community practice.
Crossover in the COURAGE trial was similar to other
evascularization trials. In the surgery trials, crossover
anged from 24% to 30% over 5 to 11 years (25–27) versus
5% over 7 years in RITA (Randomized Intervention Trial
f Angina)-2 (28) and 24% over 5 years in the MASS-II
rial (5). These high rates are simply a manifestation of the
rogressive nature of the disease, and very likely represent
he exercise of good clinical judgment. In any event,
ntention-to-treat analysis, by maintaining the advantages
f randomization, is unaffected by crossover (29).
Kereiakes et al. (2) imagine that the skewed distribution of
nginal frequency in the COURAGE trial “implies. . .2 pa-
ient populations” (1 at high risk and 1 at low risk), which
iased the conclusions against PCI (30,31). In fact, there is
othing suspicious about this pattern. If anginal frequency is
og normally distributed (32), a single population fully accounts
or these observations (Fig. 1). Thus, subgroup analyses reveal
o treatment differences between NYHA functional class 0 to
angina versus NYHA functional class II to III angina.
The contrary “premise” that the COURAGE trial com-
rised a low-risk population, based solely on a cardiac
ortality of 0.4% per year (subject to ascertainment error),
s contradicted by the magnitude of comorbidity, frequency
f inducible ischemia, and prevalence of multivessel disease.
n fact, the all-cause mortality of nearly 8% is similar to that
n the ARTS trial (21), and death or MI at 5 years is
irtually identical to that in acute coronary syndrome trials
33,34). This is not a low-risk population.
The supposition that the definition of myocardial enzyme
levation “no doubt, disadvantaged PCI” compared with
MT (2) is unsupported by the evidence. Only 26 peripro-
edural MIs occurred using this definition, and a censored
eta-Analysis of PCI in Stable Coronary Disease
Table 2 Meta-Analysis of PCI in Stable Coronary Disease
End Point OR (95% CI) p Value
Death 0.95 (0.72–1.23) 0.68
Nonfatal MI 1.32 (0.97–1.79) 0.08
Death or nonfatal MI 1.16 (0.91–1.48) 0.24
ata from Katritsis and Ioannidis (4).
Abbreviations as in Table 1.
ntegrated Analysis of theOURAGE Trial (Death or MI)
Table 3 Integrated Analysis of theCOURAGE Trial (Death or MI)
Prior OR
(95% CI)
COURAGE OR
(95% CI)
Posterior OR
(95% CI) Pr(PCI)>0%*
1.16 (0.91–1.48) 1.05 (0.87–1.27) 1.09 (0.94–1.27) 0.13
Pr(PCI)0% probability that the frequency of the primary outcome with PCI optimal medical
herapy is better than with optimal medical therapy alone, the ratio of benefit to harm being given
y the odds transformation of this probability (1  Pr)/Pr. The prior estimate is based on at
eta-analysis of previous trials of PCI versus medical therapy (4).
Abbreviations as in Table 1.nalysis that excluded these events did not shift the results
n favor of PCI, with a hazard ratio of 0.90 (95% confidence
nterval 0.73 to 1.10; p  0.29).
Finally, because DES were used infrequently in the COUR-
GE trial, Kereiakes et al. (2) say this too biased the outcomes
gainst PCI. To explore this possibility, we performed a
utative placebo analysis (20). The resultant risk ratio for
CIOMT versus OMT increased nonsignificantly (Fig. 2),
ndicating that greater use of DES, if anything, would have
een associated with a slightly greater risk of death or MI. The
laim that DES would have improved angina-free status and
uality of life (albeit likely) remains conjectural.
tage 1: “it is ridiculed”
oint. Kereiakes et al. (2) question the relevance of the
OURAGE trial to clinical practice, because “the vast
ajority of Americans [already] receive medical therapy for
heir coronary artery disease.” However, they then note that
he quality of medical therapy in the COURAGE trial is
ot achievable in the real world. Although the COURAGE
rial excluded 10,000 patients without reference to coronary
natomy (5,100 without ischemia and 4,900 with an inad-
quate ejection fraction) (3), they stipulate that “coronary
ngiography . . . should not be denied to patients with stable
ngina pectoris,” because the “choice of therapy(s) for each
ndividual patient must be made based on coronary ana-
Figure 1 Simulated Distribution of Anginal
Frequency in the COURAGE Trial
Simulated anginal frequency (episodes per week) for 1,000 hypothetical
patients. If anginal frequency (f ) is log normally distributed, with mean  and
median m, then log(f ) is unimodal with mean log(m) and variance 2log(/m)
(32). Given   10 and m  3, (as reported in the COURAGE trial [3,30]),
12.2% of patients are angina free (0 episodes per week) and 27.7% manifest
more than daily angina (7 episodes per week). In the COURAGE trial, 12.4%
were angina free and 21.1% manifested New York Heart Association functional
class III angina at baseline. The COURAGE investigators recently corrected the
mean value from   10 to   6 (31). Because the mean of the log trans-
formed distribution depends only on the median of the untransformed distribu-
tion, this correction has little effect on the simulation. Using   6 and m 
3, 16.6% are angina-free and 20.3% manifest more than daily angina.omic suitability” (2).
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October 16, 2007:1604–9 On the Management of Stable Coronary Diseaseounterpoint. The contention that most patients already
eceive medical therapy is highly suspect. While the actual
umbers are open to debate, the simple fact is that many
atients with stable angina (and an additional number of
symptomatic patients) are undergoing PCI without having
eceived sufficient medical therapy. On the conservative
ssumption that 1 million procedures are being performed
ach year, at least 30% of them in stable patients who could
therwise be treated medically (2), that is 300,000 proce-
ures that might be deferred. Even if one-third of them
ventually cross over to revascularization, that is still
00,000 fewer procedures—at a saving of at least $6 billion
nnually at current levels of reimbursement. Formal assess-
ents of cost-effectiveness and quality of life are unlikely to
ontravene these projections (35).
Nevertheless, the suboptimal quality of medical therapy
utside of the COURAGE trial remains a problem. Many
atients are not treated at all, and those who are do not
dhere to treatment for very long (36). But, the recommen-
ation of unconditional coronary angiography is no solution
nd might encourage unnecessary revascularizations. Bad
ehavior by some cannot justify equally bad behavior by
thers. The preferable solution would be better medical
reatment rather than more intervention.
The COURAGE trial itself provides the best justification
or improving the quality of medical therapy, and payers are
Figure 2 Imputed Effect of Drug-Eluting Stents in the COURAGE
Imputed effect of drug-eluting stents in the COURAGE trial by which the risk ratio (
from the RR for bare-metal stents (BMS) versus OMT in the COURAGE trial multipl
cal literature (22). PCI  percutaneous coronary intervention; PES  paclitaxal-elu
stent (Cypher, Cordis Corp., Miami Lakes, Florida). Squares represent mean RR, a
ntegrated Analysis of the COURAGE Trial (Angina-Free Status)
Table 4 Integrated Analysis of the COURAGE Trial (Angina-Free
COURAGE RR (95% CI) Pr(PCI) >0%
1 yr 0.89 (0.83–0.96) 1.00
3 yrs 0.92 (0.87–0.98) 0.99
5 yrs 0.98 (0.90–1.06) 0.72
Pr(PCI) X%  probability that angina-free status with PCI  optimal medical therapy is at leas
RR  risk ratio; other abbreviations as in Table 1.eginning to take note. Aetna (among others) is now
ffering proven preventive medications such as those in the
OURAGE trial free of charge to patients with known
eart disease or diabetes (37). It is trials such as the
OURAGE trial that encourage such innovations.
mplications
n the end, the inference in the COURAGE trial is not that
MT is better than PCI, but that an initial recommenda-
ion of PCIOMT offers no important advantage over an
nitial recommendation of OMT alone (38). Percutaneous
oronary intervention can be reserved for a later time with
ittle risk that an unfavorable event will intervene. As was
rue in the CASS (Coronary Artery Surgery Study), a
ait-and-see strategy is justified.
Why will so many of us resist this rational and prudent
onclusion (13)? Some will point to the personal, profes-
ional, and political capital that is at stake, but there are
eeper reasons. In his landmark sociologic dissection of the
edical profession, Eliot Freidson identifies 5 traits that
haracterize the typical clinician (39):
We believe in what we are doing. When things go right,
we take the credit.
l
r drug-eluting stents (DES) versus optimal medical therapy (OMT) was imputed
the RR for DES versus BMS from a meta-analysis of historical trials in the medi-
ent (Taxus, Boston Scientific, Natick, Massachusetts); SES  sirolimus eluting
izontal rules represent 95% confidence interval (CI).
us)
Pr(PCI) >5% Pr(PCI) >10% Pr(PCI) >15%*
0.96 0.58 0.10
0.81 0.25 0.02
0.27 0.04 0.00
tter than with optimal medical therapy alone using a uniform prior distribution.Tria
RR) fo
ied by
ting st
nd horStat
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On the Management of Stable Coronary Disease October 16, 2007:1604–9We prefer action to inaction. Even action with little
chance of success is preferred over no action at all.
We are pragmatic. We see apparent cause-effect relation-
ships even in the absence of any theoretic foundation.
We are highly subjective. We depend more on “gut
feelings” than on “book knowledge.”
We emphasize uncertainty in our defense. When things
go wrong, it is not our fault. Because we deal with
individuals rather than groups, we cannot rely on
epidemiologic concepts or probabilities derived from
population statistics.
Although these traits usually serve us well, they invite
ntellectual gerrymandering. Thus, when the evidence con-
icts with our judgment we tend to resist it, but when the
vidence is consistent with our judgment we tend to
mbrace it. As a result, if there is even a 1% chance that
ome technologic advance is marginally better than the
tatus quo (think tissue plasminogen activator versus strep-
okinase or bivalirudin versus heparin), we act as if it is a
ertainty and discount the downside.
The Centers for Disease Control, however, report that
oronary heart disease deaths in the U.S. fell not 1% but
ore than 40% from 1980 to 2000 (40). Nearly one-half of
his drop was attributable to treatment of conventional risk
actors and only 7% to revascularization. According to the
tudy’s senior author, “There has been a huge amount of
oney spent on angioplasty and [bypass surgery], with the
revailing understanding that it prevents deaths, but this is
he flashy stuff and it doesn’t make a great deal of difference”
41).
It takes COURAGE to say that.
eprint requests and correspondence: Dr. George A. Diamond,
408 Wild Oak Drive, Los Angeles, California 90068. E-mail:
adiamond@pol.net.
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